NRx names Richard Narido interim CFO; Seth Van Voorhees resigns Sept 30

NRX Pharmaceuticals, Inc.

Seth Van Voorhees resigned as CFO effective Sept 30, 2023, no disagreement cited.
Richard Narido appointed interim CFO effective Sept 13, 2023, via LifeSci Advisors consulting agreement.
Narido previously CFO of Lucira Health until Pfizer acquisition in April 2023.
LifeSci Agreement term is two years; includes non-competition/non-solicitation and placement fee provisions.
Agreement prohibits solicitation of LifeSci-introduced professionals for one year, with 15% placement fee.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Seth Van Voorhees

Chief Financial Officer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2023-09-30
Successor: Richard Narido
Filed: September 14, 2023, 7:59 PM ET

On September 11, 2023, Seth Van Voorhees, Ph.D., resigned from his position as the Chief Financial Officer of the Company. His resignation will be effective as of September 30, 2023, in order to facilitate a smooth transition.

Appointed (interim)

Richard Narido

Interim Chief Financial Officer

NRXP · NRX Pharmaceuticals, Inc.

Effective: 2023-09-13
Filed: September 14, 2023, 7:59 PM ET

on September 13, 2023, the Company appointed Richard Narido, 45, to serve as Interim Chief Financial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Seth Van Voorhees resigned as Chief Financial Officer at NRX Pharmaceuticals, Inc..

Action: resigned
Role: Chief Financial Officer

Exact text from the filing

On September 11, 2023, Seth Van Voorhees, Ph.D., resigned from his position as the Chief Financial Officer of the Company. His resignation will be effective as of September 30, 2023, in order to facilitate a smooth transition.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Richard Narido was appointed as Interim Chief Financial Officer at NRX Pharmaceuticals, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

on September 13, 2023, the Company appointed Richard Narido, 45, to serve as Interim Chief Financial Officer of the Company.

View on SEC.gov

NRX Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-100780

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.